NAPHCON FORTE
Clinical safety rating
cautionComprehensive clinical and safety monograph for NAPHCON FORTE (NAPHCON FORTE).
Naphazoline acts as an agonist at alpha-adrenergic receptors in the vascular smooth muscle of the conjunctiva, causing vasoconstriction and reducing redness.
| Metabolism | Metabolized in the liver via oxidative deamination. |
| Excretion | Renal excretion of unchanged drug (65%) and metabolites (35%); less than 1% fecal. |
| Half-life | Terminal elimination half-life is 9-11 hours; clinically, steady state is reached after 2-3 days of regular dosing. |
| Protein binding | Approximately 85% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd approximately 2.0 L/kg; indicates extensive distribution into body tissues. |
| Bioavailability | Topical ophthalmic: systemic absorption is minimal (<10%) due to local administration and dilution by tears. |
| Onset of Action | Topical ophthalmic: 5-10 minutes. |
| Duration of Action | Topical ophthalmic: 6-8 hours; may require q.i.d. dosing for sustained effect. |
| Molecular Weight | 246.31 Da |
1-2 drops of 0.1% solution in the affected eye(s) every 3-4 hours as needed.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | 1 drop of 0.1% solution in the affected eye(s) every 3-4 hours as needed for children ≥6 years; for children <6 years, use only under medical supervision. |
| Geriatric use | No specific dose adjustment; monitor for systemic effects due to potential increased sensitivity. |
| 1st trimester | Avoid due to potential vasoconstriction and lack of safety data; animal studies show some risk. |
| 2nd trimester | Use with caution only if clearly needed; monitor for maternal hypertension and fetal heart rate. |
| 3rd trimester | Avoid near term; may cause uterine vasoconstriction and fetal hypoxia. |
Clinical note
Comprehensive clinical and safety monograph for NAPHCON FORTE (NAPHCON FORTE).
| Placental transfer | Naphazoline is known to cross the placenta; extent not quantified but expected given low molecular weight and lipophilicity. |
| Breastfeeding | Limited data; naphazoline is excreted into breast milk in small amounts. Avoid use in nursing mothers due to risk of infant vasoconstriction and apnea. |
| Lactation Rating | L4 - Possibly Hazardous |
| Teratogenic Risk | Pregnancy Category C. Naphazoline, an imidazoline derivative, has not been studied in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 24 mg/kg/day (oral) in rats and rabbits. However, systemic absorption from ophthalmic use is minimal, but potential fetal risks are unknown. First trimester: Use only if clearly needed; no specific teratogenic data. Second and third trimesters: May cause maternal hypertension or bradycardia with systemic absorption, but no direct fetal effects reported. Labor and delivery: Not evaluated. |
| Fetal Monitoring | Monitor maternal blood pressure and heart rate, especially if used frequently or in large doses. Assess for ocular irritation or systemic effects (e.g., tachycardia, hypertension). Fetal monitoring not routinely indicated due to minimal systemic absorption. In cases of accidental overdose or prolonged use, consider fetal heart rate monitoring. |
| Fertility Effects | No data on effects on human fertility. Animal studies: No impairment of fertility observed in rats at oral doses up to 24 mg/kg/day. However, systemic sympathomimetic effects may theoretically affect reproductive function, but data are lacking. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to naphazoline or any componentAngle-closure glaucomaPatients with rhinitis siccaConcomitant use with MAOIs or within 14 days of MAOI therapy
| Precautions | Prolonged use may cause rebound hyperemia. Use with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, diabetes, or angle-closure glaucoma. |
| Food/Dietary | No significant food interactions. |
| Clinical Pearls | Naphcon Forte (naphazoline 0.1%) is a potent ophthalmic vasoconstrictor. Use with caution in patients with narrow-angle glaucoma, cardiovascular disease, hypertension, hyperthyroidism, or diabetes. Rebound congestion can occur with prolonged use (>72 hours). Do not use in patients with prior hypersensitivity to sympathomimetics. |
| Patient Advice | Do not use for more than 3 days to avoid rebound redness. · Remove contact lenses before instillation; wait 15 minutes before reinserting. · Do not touch the dropper tip to any surface to prevent contamination. · Discontinue and consult a doctor if eye pain, vision changes, or persistent redness occur. |
Loading safety data…